Inhibition of topoisomerase II by liriodenine

Biochemical Pharmacology

Volumn 54, Issue 4, 1997, Pages 467-473

  Woo, Sung Ho ^a   Reynolds, Marc C ^a   Sun, Nan Jun ^a   Cassady, John M ^a   Snapka, Robert M ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Antineoplastic; Aporphine; Cytotoxic; Multidrug resistance; Topoisomerase II; Topoisomerase inhibitor

Indexed keywords

AMSACRINE; ETOPOSIDE; GYRASE INHIBITOR; LIRIODENINE; VERAPAMIL;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DNA CROSS LINKING; ENZYME INHIBITION; HUMAN; MONKEY; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DNA BINDING; SIMIAN VIRUS 40;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APORPHINES; CELLS, CULTURED; CERCOPITHECUS AETHIOPS; DNA; DNA TOPOISOMERASES, TYPE II; ENZYME INHIBITORS; ETOPOSIDE; HUMANS;

EID: 0030921732     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(97)00198-6     Document Type: Article

References (36)

1. Ginaudeau H, Leboeuf M and Cave A, Aporphine alkaloids. Lloydia 38: 275-338, 1975.
2. Nimgirawath S and Taylor WC, Photochemical synthesis of 8H-benzo[g]-1,3-benzodioxolo-[6,5,4-de]quinolin-8-one (Liriodenine) via 7-methyl-6,7-dihydro-5H-benzo[g]-1,3-benzodioxolo[6,5,4-de]quinoline. Aust J Chem 36: 1061-1065, 1983.
3. Dong XP, Modranodnra IO, Che CT, Fong HS and Farnsworth NR, Kmeriol and other aromatic constituents of Kmeria duperreana. Pharmacol Res 6: 637-640, 1989.
4. Warthen D, Gooden EL and Jacobson M, Tumor inhibitors: Liriodenine, a cytotoxic alkaloid from Annona plabra. J Pharm Sci 58: 637-638, 1969.
5. Clark AM, Watson ES, Ashfaq MK and Hufford CD, In vivo efficacy of antifungal oxoaporphine alkaloids in experimental disseminated candidiasis, Pharmacol Res 4: 495-498, 1987.
6. Hufford CD, Funderburk MJ, Morgan JM and Robertson LW, Two antimicrobial alkaloids from heartwood of Liriodendron tulipifera L. J Pharm Sci 64: 789-792, 1975.
7. Nozaka T, Watanabe F, Tadaki S, Ishino M, Morimoto I, Kunitomo J, Ishii H and Natori S, Mutagenicity of isoquinoline alkaloid, especially of the aporphine type. Mutat Res 240: 267-279, 1990.
8. Tadaki S, Nozaka T, Yamada S, Ishino M, Morimoto I, Tanaka A and Kunitomo J, Clastogenicity of aporphine alkaloids in vitro. J Pharmacobiodyn 15: 501-512, 1992.
9. Snapka RM, Ferrer CA, Sun NJ and Cassady JM, Drug discovery and evaluation with SV40. In: The SV40 Replicon Model for Analysis of Anticancer Drugs (Ed. Snapka RM), pp. 127-148. Academic Press, San Diego, 1996.
10. Snapka RM, Papovavirus models for mammalian replicons. In: The SV40 Replicon Model for Analysis of Anticancer Drugs (Ed. Snapka RM), pp. 1-3. Academic Press, San Diego, 1996.
11. Hirt B, Selective extraction of polyoma DNA from infected mouse cell cultures. J Mol Biol 26: 365-369, 1967.
12. Snapka RM, Permana PA, Marquit G and Shin C-G, Two-dimensional agarose gel analysis of simian virus 40 DNA replication intermediates. Methods Companion Methods Enzymol 3: 73-82, 1991.
13. Permana PA, Snapka RM, Shen LL, Chu DTW, Clement JJ and Plattner JJ, Quinobenoxazines: A class of novel antitumor quinolones and potent mammalian DNA topoisomerase II catalytic inhibitors. Biochemistry 33: 11333-11339, 1994.
14. Permana PA, Ferrer CA and Snapka RM, Inverse relationship between catenation and superhelicity in newly replicated simian virus 40 daughter chromosomes. Biochem Biophys Res Commun 201: 1510-1517, 1994.
15. Shin C-G, Strayer JM, Wani MA and Snapka RM, Rapid evaluation of topoisomerase inhibitors: Caffeine inhibition of topoisomerases in vivo. Teratogenesis Carcinog Mutagen 10: 41-52, 1990.
16. Miller KG, Liu LF and Englund PT, A homogeneous type II DNA topoisomerase from HeLa cell nuclei. J Biol Chem 256: 9334-9339, 1981.
17. Muller MT, Helal K, Soisson S and Spitzner JR, A rapid and quantitative microtiter assay for eukaryotic topoisomerase II. Nucleic Acids Res 17: 9499-9503, 1989.
18. Cesarone CF, Bolognesi C and Santi L, Improved microfluorometric DNA determination in biological material using 33258 Hoechst. Anal Biochem 100: 188-197, 1979.
19. Snapka RM and Yamasaki EF, Topoisomerase II and termination of DNA replication. The SV40 Replicon Model for Analysis of Anticancer Drugs (Ed. Snapka RM), pp. 65-100. Academic Press, San Diego, 1996.
20. Snapka RM, Topoisomerase inhibitors can selectively interfere with different stages of simian virus 40 DNA replication. Mol Cell Biol 6: 4221-4227, 1986.
21. Roca J, Ishida R, Berger JM, Andoh T and Wang JC, Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase Il by trapping the enzyme in the form of a closed protein clamp. Proc Natl Acad Sci USA 91: 1781-1785, 1994.
22. Fisher GA, Lum BL, Hausdorff J and Sikic BI, Pharmacological considerations in the modulation of multidrug resistance. Eur J Cancer 32A: 1082-1088, 1996.
23. Wigler PW, Reversal of multidrug resistance in cancer cells. J Natl Cancer Inst 86: 148-149, 1994.
24. Germann UA, P-glycoprotein - A mediator of multidrug resistance in tumour cells. Eur J Cancer 32A: 927-944, 1996.
25. Yalowich JC and Ross WE, Verapamil-induced augmentation of etoposide accumulation in L1210 cells in vitro. Cancer Res 45: 1651-1656, 1985.
26. Zwelling LA, Mayes J, Hinds M, Chan D, Altschuler E, Carroll B, Parker E, Deisseroth K, Radcliffe A, Seligman M, Li L and Farquhar D, Cross-resistance of an amsacrine-resistant human leukemia line to topoisomerase II reactive DNA intercalating agents. Evidence for two topoisomerase II directed drug actions. Biochemistry 30: 4048-4055, 1991.
27. Page BD and Snyder M, Chromosome segregation in yeast. Annu Rev Microbiol 47: 231-261, 1993.
28. Center MS, Non-P-glycoprotein multidrug resistance in cell lines which are defective in the cellular accumulation of drug. Cytotechnology 12: 109-125, 1993.
29. Sperry AO, Blasquez VC and Garrard WT, Dysfunction of chromosomal loop attachment sites: Illegitimate recombination linked to matrix association regions and topoisomerase II. Proc Natl Acad Sci USA 86: 5497-5501, 1989.
30. Bae Y-S, Kawasaki I, Ikeda H and Liu LF, Illegitimate recombination mediated by calf thymus DNA topoisomerase II in vitro. Proc Natl Acad Sci USA 85: 2076-2080, 1988.
31. Bae Y-S, Chiba M, Ohira M and Ikeda H, A shuttle vector for analysis of illegitimate recombination in mammalian cells: Effects of DNA topoisomerase inhibitors on deletion frequency. Gene 101: 285-289, 1991.
32. Dillehay LE, Denstman SC and Williams JR, Cell cycle dependence of sister chromatid exchange induction by DNA topoisomerase II inhibitors in Chinese hamster V79 cells. Cancer Res 47: 206-209, 1987.
33. Negrini M, Felix CA, Martin C, Lange BJ, Nakamura T, Canaani E and Croce CM, Potential topoisomerase II DNA-binding sites at the breakpoints of a t(9;11) chromosome translocation in acute myeloid leukemia. Cancer Res 53: 4489-4492, 1993.
34. Pedersen-Bjergaard J and Philip P, Balanced translations involving chromosome bands 11q23 and 21q22 are highly characteristic of myelodysplasia and leukemia following therapy with cytostatic agents targeting at DNA-topoisomerase II. Blood 78: 1147-1148, 1991.
35. Ferguson LR and Baguley BC, Topoisomerase II enzymes and mutagenicity. Environ Mol Mutagen 24: 245-261, 1994.
36. Pommier Y, Zwelling LA, Kao-Shan C-S, Whang-Peng J and Bradley MO, Correlations between intercalator-induced DNA strand breaks and sister chromatid exchanges, mutations, and cytotoxicity in Chinese hamster cells. Cancer Res 45: 3143-3149, 1985.